Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome

Gayathri, R; Aruna, T; Sivaraman, Malar; Shilpa, Bennur; Dhanasekar, Karukkupalayam Ramasamy

doi:10.1007/s00384-019-03462-4

Cited by 26 publications

(29 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 87 RCTs on IBS, 45 RCT (50 treatment arms) were then excluded, as there was only one RCT/type (Supplementary appendix, Table 1 ). As a result, 42 RCTs (45 treatment arms) were included in the systematic review ( N = 3856) [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] . For the meta-analysis, two RCTs testing E. coli Nissle 1917 were excluded [ 27 , 28 ] as no common IBS outcome measurement was used.…”

Section: Resultsmentioning

confidence: 99%

“…We were unable to perform a sub-group analysis comparing efficacy of specific probiotic strains done in low-risk versus high-risk bias trials, as only one trial had a high risk of overall bias . 46 Within bias domains, most high risk bias ratings were due to two reasons: 48% did not report if the study group allocator was blinded and 31% did not report the method of randomization used. Of the other domains of study bias (performance, detection, attrition, reporting and other), most were rated of low bias in each of these domains.…”

Section: Assessment Of Study Qualitymentioning

confidence: 99%

See 1 more Smart Citation

Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis

2021

View full text Add to dashboard Cite

Background: Consistent guidance for choosing an appropriate probiotic for the treatment of irritable bowel syndrome is lacking. Methods: Literature databases searched included: PubMed, Google Scholar and NIH registry of clinical trials from inception to June 2021. Inclusion criteria: randomized controlled trials (RCTs) enrolling adult or pediatric IBS patients comparing probiotics against controls and 2 RCTs with common IBS outcome measures within each type of probiotic. Five common measures of IBS symptoms (changes in global Irritable Bowel Syndrome Severity Scoring System or IBS-SSS scores, frequency of global responders, changes in bloating or abdominal pain scores and frequency of abdominal pain relief) were used. This study was registered at Prospero (#CRD42018109169). Findings: We screened 521 studies and included 42 randomized controlled trials (45 treatment arms, N = 3856). Four probiotics demonstrated significant reduction in abdominal pain relief: B. coagulans MTCC5260 (RR= 4 . 9, 95% C.I. 3 . 3, 7 . 3), L. plantarum 299v (RR= 4 . 6, 95% CI 1 . 9, 11 . 0), S. boulardii CNCM I-745 (RR= 1 . 5, 95% C.I. 1 . 1, 2 . 1) and S. cerevisiae CNCM I-3856 (RR= 1 . 3, 95% C.I. 1 . 04, 1 . 6). Mild-moderate adverse events were reported in 51% of the trials, none were more associated with the probiotic compared to controls. Interpretation: Although the analysis of probiotic efficacy was limited by the diversity of IBS outcomes used in trials and lack of confirmatory trials for some strains, six single-strain probiotics and three different types of probiotic mixtures showed significant efficacy for at least one IBS outcome measure. These results might be relevant to clinical practice and policy.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Assessment Of Study Qualitymentioning

confidence: 99%

Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis

2021

View full text Add to dashboard Cite

show abstract

“…There are evidences about its involvement in colitis (Iliev et al 2012), in particular in IBD (Sokol et al 2017;Di Paola et al 2020) and, not last, in stress-induced visceral hypersensitivity (Botschuijver et al 2017). It has also been reported that some metabolic products of yeast metabolism could lead to symptoms related to IBS, and that fungal βglucans of the cell wall that are normally recognized by the host immune system can induce visceral hypersensitivity (Botschuijver et al 2017;Gayathri et al 2020) and differential immune responses (Rizzetto et al 2016;Di Paola et al 2020).…”

Section: Discussionmentioning

confidence: 99%

Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients

Sciavilla

Strati

Paola

et al. 2021

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Studies so far conducted on irritable bowel syndrome (IBS) have been focused mainly on the role of gut bacterial dysbiosis in modulating the intestinal permeability, inflammation, and motility, with consequences on the quality of life. Limited evidences showed a potential involvement of gut fungal communities. Here, the gut bacterial and fungal microbiota of a cohort of IBS patients have been characterized and compared with that of healthy subjects (HS). The IBS microbial community structure differed significantly compared to HS. In particular, we observed an enrichment of bacterial taxa involved in gut inflammation, such as Enterobacteriaceae, Streptococcus, Fusobacteria, Gemella, and Rothia, as well as depletion of health-promoting bacterial genera, such as Roseburia and Faecalibacterium. Gut microbial profiles in IBS patients differed also in accordance with constipation. Sequence analysis of the gut mycobiota showed enrichment of Saccharomycetes in IBS. Culturomics analysis of fungal isolates from feces showed enrichment of Candida spp. displaying from IBS a clonal expansion and a distinct genotypic profiles and different phenotypical features when compared to HS of Candida albicans isolates. Alongside the well-characterized gut bacterial dysbiosis in IBS, this study shed light on a yet poorly explored fungal component of the intestinal ecosystem, the gut mycobiota. Our results showed a differential fungal community in IBS compared to HS, suggesting potential for new insights on the involvement of the gut mycobiota in IBS. Key points • Comparison of gut microbiota and mycobiota between IBS and healthy subjects • Investigation of cultivable fungi in IBS and healthy subjects • Candida albicans isolates result more virulent in IBS subjects compared to healthy subjects

show abstract

“…More importantly, the aforementioned results focused on the characterization of fungal communities in CD and/or a mixed UC and CD patients or experimental models; further independent studies about the variation of gut fungal communities in UC patients or experimental models are needed. Interestingly, S. cerevisiae is a beneficial fungus that has capacity to ameliorate gastroenteritis [3,138], mitigate adherent-invasive Escherichia coli (AIEC)induced colitis in CEACAM6 (carcinoembryonic antigen-related cell adhesion molecule 6) -expressing mice [139], and relieve abdominal pain in irritable bowel syndrome (IBS) in human subjects [140]. Therefore, the modulation of intestinal mycobiota may be a potential target for treating IBD.…”

Section: Gut Mycobiota and Intestinal Diseasesmentioning

confidence: 99%

Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities

Xia

et al. 2021

Microbiome

View full text Add to dashboard Cite

Bacteria, viruses, protozoa, and fungi establish a complex ecosystem in the gut. Like other microbiota, gut mycobiota plays an indispensable role in modulating intestinal physiology. Notably, the most striking characteristics of intestinal fungi are their extraintestinal functions. Here, we provide a comprehensive review of the importance of gut fungi in the regulation of intestinal, pulmonary, hepatic, renal, pancreatic, and brain functions, and we present possible opportunities for the application of gut mycobiota to alleviate/treat human diseases.

show abstract

Efficacy of Saccharomyces cerevisiae CNCM I-3856 as an add-on therapy for irritable bowel syndrome

Cited by 26 publications

References 14 publications

Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis

Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis

Gut microbiota profiles and characterization of cultivable fungal isolates in IBS patients

Intestinal mycobiota in health and diseases: from a disrupted equilibrium to clinical opportunities

Contact Info

Product

Resources

About